Search research articles
Contact Us
Filters
Showing results (111-120 of 135) with videos related to
Page
of 14
Sort By:
European Urology Oncology
|
November 8, 2023
Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study
Evan Y Yu, William R Berry, Howard Gurney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 20, 2023
A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer
David Pook, Daniel M Geynisman, Joan Carles, et al.
European Urology
|
November 9, 2021
First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial
Laurence Albiges, Nizar M Tannir, Mauricio Burotto, et al.
European Urology
|
April 10, 2022
Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study
Evan Y Yu, Michael P Kolinsky, William R Berry, et al.
Scientific Reports
|
January 26, 2018
Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer
Bo Gao, Yi Lu, Annemieke J M Nieuweboer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 14, 2022
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on <i>FGFR1</i>/<i>3</i> mRNA Expression
Cora N Sternberg, Daniel P Petrylak, Joaquim Bellmunt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 5, 2025
Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial
Daniel P Petrylak, Raffaele Ratta, Nobuaki Matsubara, et al.
Future Oncology (London, England)
|
April 13, 2022
Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer
Thomas Powles, Se Hoon Park, Eric Voog, et al.
Cancer
|
April 6, 2022
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
Robert J Motzer, David F McDermott, Bernard Escudier, et al.
The New England Journal of Medicine
|
September 26, 2015
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J Motzer, Bernard Escudier, David F McDermott, et al.
Page
of 14
Search research articles
Search
Showing results (111-120 of 135) with videos related to
Sort By:
Page
of 14
European Urology Oncology
|
November 8, 2023
Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study
Evan Y Yu, William R Berry, Howard Gurney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 20, 2023
A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer
David Pook, Daniel M Geynisman, Joan Carles, et al.
European Urology
|
November 9, 2021
First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial
Laurence Albiges, Nizar M Tannir, Mauricio Burotto, et al.
European Urology
|
April 10, 2022
Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study
Evan Y Yu, Michael P Kolinsky, William R Berry, et al.
Scientific Reports
|
January 26, 2018
Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer
Bo Gao, Yi Lu, Annemieke J M Nieuweboer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 14, 2022
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on <i>FGFR1</i>/<i>3</i> mRNA Expression
Cora N Sternberg, Daniel P Petrylak, Joaquim Bellmunt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 5, 2025
Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial
Daniel P Petrylak, Raffaele Ratta, Nobuaki Matsubara, et al.
Future Oncology (London, England)
|
April 13, 2022
Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer
Thomas Powles, Se Hoon Park, Eric Voog, et al.
Cancer
|
April 6, 2022
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
Robert J Motzer, David F McDermott, Bernard Escudier, et al.
The New England Journal of Medicine
|
September 26, 2015
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J Motzer, Bernard Escudier, David F McDermott, et al.
Page
of 14